Wednesday, October 16, 2019
Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes
  SocialTwist Tell-a-Friend  

BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- Novo Nordisk announced today the results from two Ozempic (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed:

  • Ozempic was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and body weight in people with type 2 diabetes uncontrolled on metformin.1
  • Ozempic was superior to Victoza (liraglutide 1.2 mg) in reducing HbA1c and body weight in people with type 2 diabetes.2

These data were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, and simultaneously published in The Lancet Diabetes & Endocrinology (SUSTAIN 8) and Diabetes and Metabolism (SUSTAIN 10).1,2

"We are proud of the superior clinical profile of once-weekly Ozempic , as demonstrated through all the SUSTAIN clinical trials, and encouraged by these new data which further reinforce the value of Ozempic for people with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

These trials form part of the extensive SUSTAIN programme, a global clinical development programme that comprises more than 10 Phase 3 trials involving more than 10,065 adults with type 2 diabetes. To date, outcomes of SUSTAIN 1-7 and 9 have been published demonstrating Ozempic is a best-in-class, efficacious and well-tolerated treatment option for people with type 2 diabetes.


At 52 weeks, Ozempic demonstrated a superior reduction in mean HbA1c of 1.5% compared to canagliflozin at 1.0%, from a baseline of 8.3%. In addition, 66.1% of people treated with Ozempic achieved HbA1c treatment target <7% vs 45.1% of those treated with canagliflozin. People treated with Ozempic also demonstrated superior reductions in body weight compared with canagliflozin with 5.3 kg vs 4.2 kg, respectively, from a mean baseline of 90.2 kg. Significantly more people treated with Ozempic achieved reduction in body weight of ≥10% vs canagliflozin (22.3% vs 8.9%, respectively).

"To date, head-to-head trials of GLP-1 receptor agonists and SGLT-2 inhibitors have been limited," said Dr Ildiko Lingvay, University of Texas Southwestern Medical Centre, Dallas, and lead study investigator. "These data seen in the SUSTAIN 8 trial support Ozempic as an efficacious treatment option for reducing blood sugar and body weight for people with type 2 diabetes after metformin."


At 30 weeks, Ozempic demonstrated a superior reduction in mean HbA1c compared to Victoza (1.7% vs 1.0% respectively), from a mean baseline of 8.2%. In addition, 80% of people treated with Ozempic achieved HbA1c treatment target of <7% vs 46% of those treated with Victoza . People treated with Ozempic also demonstrated superior reductions in body weight compared with Victoza with 5.8 kg vs 1.9 kg, respectively, from a mean baseline of 96.9 kg. Significantly more people treated with Ozempic achieved reduction in body weight of ≥10% than those treated with Victoza (19% vs 4%, respectively).

"Intensifying treatment with Ozempic showed significant benefits over Victoza in terms of blood sugar control and reduction in body weight, providing an alternative treatment option for those uncontrolled on current treatment," said Dr Matthew Capehorn, Rotherham Institute for Obesity, UK, and lead study investigator.

The tolerability of once-weekly Ozempic was generally similar to that of Victoza and canagliflozin, except for higher rates of gastrointestinal adverse events (AEs) with Ozempic vs Victoza and more frequent infections and infestations with canagliflozin vs Ozempic . The safety profile of Ozempic 1.0 mg in both trials was consistent with the overall SUSTAIN clinical trial programme.

About Ozempic

Once-weekly Ozempic (semaglutide) is an analogue of human glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.3,4 Ozempic was first approved by the US FDA in 2017 and is now launched in 25 countries.


SUSTAIN 8 is a 52-week double-blinded Phase 3 trial investigating the efficacy and safety of once-weekly Ozempic (semaglutide 1.0 mg) vs canagliflozin 300 mg as add-on to metformin in people with type 2 diabetes. The primary endpoint was change in HbA1c from baseline to Week 52, and key secondary endpoints include change in body weight at Week 52 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 52.1

About SUSTAIN 10

SUSTAIN 10 is a 30-week open-label Phase 3b trial investigating the safety and efficacy of Ozempic 1.0 mg once-weekly vs Victoza 1.2 mg once-daily, as add-on to 1–3 oral antidiabetics (OADs) in 577 adults with type 2 diabetes in Europe. The primary endpoint was change in HbA1c at Week 30, and key secondary endpoints include change in body weight at Week 30 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 30.2

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit, Facebook, Twitter, LinkedIn, YouTube.


  1. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. Published Online 17 September 2019.
  2. Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab (2019).
  3. EMA. Ozempic Summary of Product Characteristics. Available at: Last accessed: September 2019.
  4. FDA. Ozempic US Prescribing Information. December 2017. Available at: Last accessed: September 2019.

Further information


Mette Kruse Danielsen

+45 3079 3883

Ken Inchausti (US)

+1 609 240 9429


Peter Hugreffe Ankersen

+45 3075 9085

Kristoffer Due Berg (US)

+1 609 235 2989

Valdemar Borum Svarrer

+45 3079 0301

Ann Søndermølle Rendbæk

+45 3075 2253

More News by PR Newswire India

Vu Televisions Emerge as Market Leaders in Large Size and 4K Category in India

A Holistic Approach to Food and Nutrition Security This World Food Day

APU Celebrates its 3rd Convocation

SenRa and Bosch Partner to Deploy LoRaWAN® Solutions in India

LifeNet Health brings first clinically proven allograft-based biologic wound therapy to India

The Smart Contract Security Alliance Announces Founding Council

Patrick Imbardelli Elected to YPO Board of Directors

World Intellectual Property Indicators: Filings for Patents, Trademarks, Industrial Designs Reach Record Heights in 2018

Saudi Joy Forum 19, A Success For The Region And World

AIC Named North American Distributor Of Organic Rice, Organic Brown Rice And Organic Pumpkin Seed Proteins

WISPA Members Vote Cambium Networks Manufacturer of the Year

IMI and GustoMSC Sign Jack-up Design License Agreement

New Report: Laundry Releases Trillions of Plastic Microfibers Into the Ocean

FOX Bet Strikes Multiyear Deal With Major League Baseball

OhmniLabs Showcases Latest Telerobotics Innovations At CEATEC 2019

Airspan - Breaking Down the Barriers to Entry With the New Mimosa Connectorized A5x Access Point

TMP Worldwide Acquires UK-Based Social Media Leader Carve

CleverTap Completes $35 Million Series C Funding to Drive Global Growth

Charles Manning, Founder and CEO, Kochava, joins Forbes Technology Council

10th Foundation Day Celebrations Start at Shoolini University

Tourcom LLC, Holding Company of Tourcom Blockchain, Signs Strategic Investment Agreement through Equity Acquisition of Travel Information Sharing Service 'Wishbeen'

WorkBoard Announces Deeper Jira Integration to Bring Team OKRs into Developers' Jira Experience

Cision Announces Exclusive Platinum Sponsorship For PRSA 2019 International Conference

Systech Expands Market-Leading Brand Protection Solution for Improved Supply Chain Visibility

Artificial intelligence is transforming health care across Asia, fuelled by innovative public-private sector R&D and a focus on domestic health-care burdens

Sirius Design Group Generates $1.2m Revenue in 4 Years Helping Clients With Digital Real Estate

Dynata Launches New Platform to Transform the Future of Insights and Marketing

S BLOCK Co-Hosts WBF 2019 Indonesia Technology Conference, Creates DAO Super Community

TUV Rheinland Enables LoRaWAN(R) Certification in India

Tukatech Releases TUKAcad for Subscription in Native Languages for 4.38 Billion People

IDFC FIRST Bank and Sodexo Partner to Introduce Digital Meal Benefit Solution for Corporate Employees

Whale Cloud Unveils 5G Operation Map at India Mobile Congress 2019

LyondellBasell Announces Construction of New Small-Scale Molecular Recycling Facility

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

ZTE launches industry-first 5G+VDSL2 hybrid home gateway

OYO's HR Team Saved 75% At-risk Employees Using inFeedo's Engagement bot, Amber

Ameyo Integrates With Freshworks to Simplify Customer Journey

Nuclear Days 2019 - French Nuclear Industry to Intensify its Operations in Indian Market

Happiest Minds Wins 2019 Red Herring Top 100 Asia Award

The Spielwarenmesse Reveals the Trends for 2020

Xinhua Silk Road: SAIC Motor gains momentum in India with 31,000 orders received by September

CreditVidya Wins the Prestigious 2019 Red Herring Top 100 Asia Award

GCW Global Customised Wealth Announces New Partner: Tim Babich

GTPL Hathway's Consolidated H1 FY20 PAT at ₹ 580 Million, up by 102%

'Where Will Man Take Us?' by Atul Jalan has been Certified a National Bestseller by Penguin Random House India

Tejas Networks Launches World's Largest Disaggregated Packet-optical Switch at India Mobile Congress 2019

Building on Local Momentum: Malaysia's Greater Petaling Joins City Cancer Challenge

Shanghai International Money Fair - one of China's largest financial fairs will be held in December

Europe's Most Trusted Crypto And Precious Metal Companies Partner To Create Gold Token Secured By Bitcoin Network

RGE Commits US$200 Million to Next-Generation Textile Fibre Innovation and Technology

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

INSIDE INFORMATION: BW LPG Contemplated Sale of Shares

School House Crafts Multi-Sensory Journey of Discovery and Re-collection for La Mer Campaign Exhibition

Vevue Partners with CBX Exchange for Initial Auction Offering

Frost & Sullivan Recognizes Pepco Holdings and Carlsbad Municipal Water District with Excellence in Resourcefulness Awards at Itron Utility Week

His Holiness The Dalai Lama Awarded Honorary Doctorate by Chitkara University

Surplus Keslow Cinematography Gear Up For Auction

Libyan Investment Authority Loses Claim in the UK Court of Appeal - London

Artificial Intelligence for Risk Management Process by MovingNow

Maruti Suzuki Arena Devils Circuit Season 2019-20 Draws Over 6K Runners in Hyderabad

Quectel Achieves Industry's First 5G Data Call over 5G mmWave Module

Artprice by Artmarket: The Gagosian's Grand Projects for the Late Simon Hantaï (1922-2008)

Ryan International Group of Schools Receive India's Most Respected Brand Award 2019

JD Institute Of Fashion Technology, South Announced its New Domain

VeChain Is Leading Co-sponsor of GDST Seafood Trackathons

The World's Largest Automakers, Along with MOBI, Announce a Joint Proof of Concept for the First Vehicle Identity on Blockchain

Indiannica Learning Announces the Launch of Indiannica Quiz League

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

Dushyant Chautala gets threat call from ...
Delhi's air quality turns 'Very Poor' fo...
CCPA to meet for deciding on winter sess...
Odisha CM not to celebrate birthday over...
14 new institutes for media, ent skill d...
Photo voter slips printed in Braille for...
 Top Stories
Putin visits UAE during Middle East... 
Manipur: Suspected IED bomb found a... 
Wanted to make Bulgaria suffer for ... 
Never thought India could defeat Pa... 
WB govt should apologise: Mukul Roy... 
Hong Kong-based company to invest U... 
PM Modi to hold 3 rallies in poll-b... 
INX Media case: 3 member ED team re...